Normalized wall thickness at MRE predicts clinical remission in Crohn's disease after infliximab discontinuation: a 5 years follow-up

被引：4
|
作者：
Annunziata, M. L. [1 ]
Papparella, L. G. [1 ]
Sansoni, I. [2 ]
Balestrieri, P. [1 ]
Cicala, M. [1 ]
机构：
[1] Campus Bio Med, Gastroenterol, Rome, Italy
[2] Campus Bio Med, Radiol, Rome, Italy
来源：
JOURNAL OF CROHNS & COLITIS | 2014年 / 8卷
关键词：
D O I：
10.1016/S1873-9946(14)60522-5
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P402
引用
收藏
页码：S233 / S233
页数：1
相关论文
共 50 条
  • [1] Normalized Wall Thickness At MRE Predicts Clinical Remission in Crohn's Disease After Infliximab Discontinuation: A 5 Years' Follow-Up Study
    Annunziata, Maria Laura
    Papparella, Luigi Giovanni
    Sansoni, Ilaria
    Balestrieri, Paola
    Cicala, Michele
    GASTROENTEROLOGY, 2014, 146 (05) : S246 - S246
  • [2] Maintenance of Clinical Benefit in Crohn's Disease Patients After Discontinuation of Infliximab: Long Term Follow-up of a Single Center Cohort
    Waugh, Alistair W.
    Wong, Karen
    Fedorak, Richard N.
    GASTROENTEROLOGY, 2010, 138 (05) : S685 - S685
  • [3] Prediction of Sustained Remission After Discontinuation of Infliximab in Patients With Crohn's Disease
    Papamichail, Konstantinos
    Casteele, Niels Vande
    Hauenstein, Scott
    Princen, Fred
    Singh, Sharat
    Ferrante, Marc
    van Assche, Gert A.
    Rutgeerts, Paul J.
    Gils, Ann
    Vermeire, Severine
    GASTROENTEROLOGY, 2014, 146 (05) : S457 - S457
  • [4] Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort
    Waugh, A. W. G.
    Garg, S.
    Matic, K.
    Gramlich, L.
    Wong, C.
    Sadowski, D. C.
    Millan, M.
    Bailey, R.
    Todoruk, D.
    Cherry, R.
    Teshima, C. W.
    Dieleman, L.
    Fedorak, R. N.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2010, 32 (09) : 1129 - 1134
  • [5] Crohn's disease genotypes of patients in remission vs relapses after infliximab discontinuation
    Cathy Lu
    Alistair Waugh
    Robert J Bailey
    Raeleen Cherry
    Levinus A Dieleman
    Leah Gramlich
    Kata Matic
    Mario Millan
    Karen I Kroeker
    Daniel Sadowski
    Christopher W Teshima
    Dennis Todoruk
    Clarence Wong
    Karen Wong
    Richard N Fedorak
    World Journal of Gastroenterology, 2012, (36) : 5058 - 5064
  • [6] Crohn's disease genotypes of patients in remission vs relapses after infliximab discontinuation
    Lu, Cathy
    Waugh, Alistair
    Bailey, Robert
    Cherry, Raeleen
    Dieleman, Levinus A.
    Gramlich, Leah
    Matic, Kata
    Millan, Mario
    Kroeker, Karen I.
    Sadowski, Daniel
    Teshima, Christopher W.
    Todoruk, Dennis
    Wong, Clarence
    Wong, Karen
    Fedorak, Richard N.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2012, 18 (36) : 5058 - 5064
  • [7] Serology panel for prediction relapse after discontinuation of infliximab in patients with Crohn's disease achieving clinical remission
    Papamichail, K.
    Claes, K.
    de Bruyn, M.
    Hauenstein, S.
    Princen, F.
    Singh, S.
    Van Assche, G. A.
    Rutgeerts, P. J.
    Vermeire, S.
    Ferrante, M.
    JOURNAL OF CROHNS & COLITIS, 2015, 9 : S295 - S296
  • [8] Serology Panel for Prediction of Relapse After Discontinuation of Infliximab in Patients With Crohn's Disease Achieving Clinical Remission
    Papamichael, Konstantinos
    Claes, Karolien
    de Bruyn, Magali
    Princen, Fred
    Singh, Sharat
    Van Assche, Gert A.
    Rutgeerts, Paul J.
    Vermeire, Severine
    Ferrante, Marc
    Hauenstein, Scott
    GASTROENTEROLOGY, 2015, 148 (04) : S865 - S865
  • [9] Magnetic Resonance Enterography (MRE) Remission and Radiologic Healing Predicts Clinical Remission At One Year Follow-up
    Sauer, Cary G.
    Middleton, Jeremy P.
    Alazraki, Adina
    Braithwaite, Kiery
    Martin, Diego R.
    Kugathasan, Subra
    GASTROENTEROLOGY, 2013, 144 (05) : S530 - S530
  • [10] Clinical Follow-up of Patients with Behcet Uveitis after Discontinuation of Infliximab Therapy
    Kose, Helin Ceren
    Yalcindag, Nilufer
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2022, 30 (01) : 203 - 207
12345